...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: got this & sent a response/follow up minutes before …

Your guess is as good as mine.  :)

My take on this is that a very influential Zenith/ Resverlogix shareholder did some pushing.

 

 

Koo

Share
New Message
Please login to post a reply